Complicated

SPERO ALERT: Bragar Eagel & Squire, P.C. is Investigating Spero Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, November 3, 2023

Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Spero have breached their fiduciary duties to the company.
  • Spero, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing treatments for multi-drug resistant bacterial infections and rare diseases in the United States.
  • The Company's product candidates include Tebipenem Pivoxil Hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.
  • On March 31, 2022, Spero issued a press release announcing the Company’s fourth quarter and full year 2021 financial results.

Chapter Revises Its Best-seller on Medicare, Incorporating Fresh Data for 2024

Retrieved on: 
Tuesday, October 10, 2023

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231005256176/en/
    "It's Not That Complicated" 2024 book cover.
  • As we approach a fresh enrollment cycle, Parker anticipates a surge in need for Medicare information , particularly regarding changes to prescription coverage.
  • Chapter also releases a weekly newsletter and blog about the ins and outs of Medicare.
  • “We’re committed to helping people make wise decisions for the next chapter of their lives.”

Global Complicated Urinary Tract Infections Market Report to 2032 - Featuring Spero Therapeutics, Wockhardt, Venatorx Pharmaceuticals and Allecra Therapeutics Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, December 2, 2022

The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Urinary Tract Infection R&D.

Key Points: 
  • The companies and academics are working to assess challenges and seek opportunities that could influence Complicated Urinary Tract Infection R&D.
  • Major players are involved in developing therapies for Complicated Urinary Tract Infection.
  • The launch of emerging therapies will significantly impact the Complicated Urinary Tract Infection market.
  • A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Complicated Urinary Tract Infection.

Venatorx Pharmaceuticals Presents Data on Investigational Cefepime-Taniborbactam at IDWeek 2022

Retrieved on: 
Thursday, October 20, 2022

Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.

Key Points: 
  • Venatorx Pharmaceuticals, a private, clinical-stage pharmaceutical company focused on improving health outcomes for patients with difficult-to-treat drug resistant gram-negative bacterial infections and viral infections, today will present new data during IDWeek 2022 for its novel investigational antibiotic cefepime-taniborbactam.
  • The presentations, along with the four other posters detailing additional cefepime-taniborbactam data at IDWeek 2022 (see release ), will be available on the companys website.
  • We believe this data is meaningful given the sustained clinical benefit versus meropenem up to 3 to 4 weeks after treatment, said Christopher J. Burns, Ph.D. , President and CEO of Venatorx.
  • The safety data for cefepime-taniborbactam was consistent with the historical safety data for cefepime.

Less Students and Less Credit Hours; New Data Suggests Success May Lie in the Academic Schedule

Retrieved on: 
Tuesday, October 18, 2022

OVERLAND PARK, Kan., Oct. 18, 2022 /PRNewswire/ -- As students return to colleges and universities post-pandemic, they are demanding higher numbers of online, hybrid, and hyflex courses, yet the data shows students fail to consistently find success in these new modalities, according to a new data released today from Ad Astra. The report, Complicated Lives, Competing Priorities: Reimagining the Course Schedule for Today's Student, shows students took 14.6% fewer credits in fall 2021 than they did in fall 2019 and institutions grappled with how best to meet the needs of learners in a quickly evolving learning environment.

Key Points: 
  • "Intentional course scheduling puts the student and the student's needs back at the center of the success conversation, while also helping institutions create sustainable models to deliver education."
  • "Yet, we often fail to break down how we put students on intentional and structured paths to completing that credential or degree.
  • Interest in the schedule as a tool for student success, but work remains to make the schedule student centric.
  • The Software-as-a-Service (SaaS) company currently holds a United States patent for its innovative method of determining student demand for academic courses.

Nabriva Therapeutics to Report Second Quarter 2022 Financial Results and Recent Corporate Highlights on August 3, 2022

Retrieved on: 
Wednesday, July 20, 2022

ET to discuss the financial results and recent corporate highlights.

Key Points: 
  • ET to discuss the financial results and recent corporate highlights.
  • Nabriva Therapeutics is a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections.
  • Nabriva Therapeutics is also developing CONTEPO (fosfomycin) for injection, a potential first-in-class epoxide antibiotic for complicated urinary tract infections (cUTI), including acute pyelonephritis.
  • However, while Nabriva Therapeutics may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

Pomerantz Law Firm Announces the Filing of a Class Action Against Spero Therapeutics, Inc. and Certain Officers – SPRO

Retrieved on: 
Monday, July 18, 2022

NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.

Key Points: 
  • NEW YORK, July 18, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Spero Therapeutics, Inc. (Spero or the Company) (NASDAQ: SPRO) and certain of its officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.
  • The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Saturday, July 16, 2022

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Saturday, July 9, 2022

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.